Delpor announced today that it dosed the first patient in a Phase 1b/2a clinical trial for its DLP-114 risperidone implant. DLP-114 is a long-acting formulation of the antipsychotic risperidone for schizophrenia maintenance therapy. The open-label study is to evaluate the safety, tolerability and pharmacokinetics of switching from oral risperidone to the once- or twice-yearly DLP-114 […]
delpor
Delpor wins $1.5m NIH grant for diabetes drug implant
Delpor Inc. said today that it won a $1.5 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to support the development of its exenatide implant. The implant was designed for patients with Type II diabetes and features Delpor’s Nanopor technology, which uses passive diffusion to deliver therapeutic levels of exenatide […]
